A week ago, FDA posted some internal review documents on the home page for aducanumab (Aduhelm). At that time there were three; now there are a total of six.
These include the full-length review of clinical pharmacology and of statistics. (Pretty long versions were presented at the November 2020 Ad Comm meeting; but these are the "full, final" versions as of June 2021.)
The released FDA documents are these: